MGTX MeiraGTx Holdings plc
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1735438 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,365.9%
TTM net income YoY146.4%
TTM EPS YoY141.2%
Revenue 3-yr CAGR291.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin44.8%
Net margin19.5%
FCF margin-0.7%
EBITDA margin47.8%
Returns
ROE89.7%
ROA26.0%
ROIC (approx.)—
Asset turnover1.34x
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.00x
Current ratio4.62x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio25.6%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.81M | $321.43M | $293,000 | $75.36M | $410,000 | $3.69M | $1.93M | $21.39M |
| R&D expense | $39.32M | $57.83M | $31.98M | $30.81M | $32.53M | $33.49M | $32.78M | $23.98M |
| SG&A expense | $11.95M | $12.01M | $8.93M | $17.60M | $13.62M | $12.31M | $9.36M | $17.09M |
| Operating income | -$49.88M | $244.43M | -$40.82M | $26.47M | -$46.05M | -$44.79M | -$41.60M | -$31.49M |
| Interest expense | — | $3.51M | $2.85M | $3.06M | $3.06M | $3.03M | $3.04M | $3.41M |
| Income tax | $613,000 | $2.36M | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$51.21M | $160.72M | -$46.31M | $15.09M | -$50.51M | -$38.80M | -$39.98M | -$39.40M |
| EBITDA | -$47.03M | $247.25M | -$37.81M | $29.59M | -$42.90M | -$41.60M | -$38.52M | -$28.42M |
| EPS (basic) | -0.53 | 1.76 | -0.57 | — | -0.62 | -0.48 | -0.51 | — |
| EPS (diluted) | -0.53 | 1.71 | -0.57 | — | -0.62 | -0.48 | -0.51 | — |
| Weighted avg. shares (diluted) | 96.88M | 93.81M | 81.30M | — | 80.95M | 80.59M | 79.03M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $184.65M | $143.17M | $71.54M | $65.93M | $17.11M | $34.42M | $68.61M | $105.67M |
| Receivables | — | — | $3.26M | $3.00M | $2.81M | $2.32M | $734,000 | $707,000 |
| Inventory | — | — | — | — | — | $314,000 | $607,000 | $385,000 |
| Current assets | $242.35M | $218.35M | $96.20M | $91.76M | $34.17M | $47.08M | $79.89M | $123.52M |
| PP&E, net | $96.87M | $100.33M | $102.57M | $105.47M | $107.65M | $110.82M | $104.41M | $102.88M |
| Intangibles | $17,000 | $421,000 | $494,000 | $578,000 | $653,000 | $742,000 | $773,000 | $821,000 |
| Total assets | $411.69M | $396.45M | $244.66M | $244.43M | $189.47M | $198.72M | $224.01M | $269.75M |
| Current liabilities | $52.40M | $58.10M | $176.13M | $122.56M | $152.92M | $53.44M | $52.37M | $60.78M |
| Total liabilities | $196.47M | $180.67M | $302.79M | $250.22M | $230.03M | $195.76M | $190.91M | $201.92M |
| Shareholders' equity | $215.08M | $215.57M | -$58.13M | -$5.79M | -$40.56M | $2.96M | $33.10M | $67.83M |
| Shares outstanding | 97.62M | 94.19M | 81.45M | 81.12M | 80.48M | 80.45M | 79.42M | 78.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24.55M | -$38.54M | $17.81M | $46.63M | -$12.21M | -$43.95M | -$36.83M | -$23.28M |
| Capital expenditure | $1.73M | $332,000 | $2.01M | $272,000 | $610,000 | $1.23M | $1.71M | $1.22M |
| Free cash flow | -$26.28M | -$38.87M | $15.80M | $46.36M | -$12.82M | -$45.18M | -$38.54M | -$24.49M |
| Investing cash flow | -$1.73M | -$23.64M | -$2.26M | -$1.09M | -$547,000 | -$761,000 | -$1.71M | -$1.22M |
| Financing cash flow | $67.77M | $133.90M | -$10.11M | $5.33M | -$219,000 | $5.45M | $1.71M | $4.24M |
| Depreciation & amortization | $2.85M | $2.82M | $3.01M | $3.12M | $3.15M | $3.19M | $3.08M | $3.07M |
| Stock-based compensation | $7.66M | $3.78M | $3.65M | $5.60M | $5.95M | $5.66M | $4.89M | $6.12M |
| Share buybacks | $0 | $0 | $18.19M | — | — | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.